Letermovir Prophalaxis for CMV in Haplo HSCT - Early Experience from Single Center Fron North India

Key Points

• Prophylaxis with letermovir effectively reduces CMV incidence in haplo HSCT recipients, enhancing patient safety.
• In the study, a significant reduction in CMV viremia cases was observed during follow-up, indicating a clear benefit.
• Observational analysis across a single center in North India assessed the impact of letermovir on CMV outcomes.
• This finding highlights the potential for improved antiviral strategies in stem cell transplant settings.